Reg 34(1)-Annual Report for Financial Year 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has re-submitted its 48th Annual Report for FY 2024-25 to BSE under the SEBI Listing Regulations compliance tab, with no changes from the earlier version. The 48th AGM is scheduled for Friday, 5th September 2025 at 4:00 PM via video conferencing. On a consolidated basis, the company posted revenue from operations of ₹3,249.18 lakhs (up over 16% year-on-year), profit after tax of ₹174.08 lakhs (nearly doubled), and an improved EBITDA margin of 9.46% (from 6.4% last year). The company also expanded into container leasing and logistics via a subsidiary (with 800+ TEU containers deployed) and launched Eiko Scientific Solutions LLP for specialty chemicals R&D. Shareholders will vote on key items including a hike in authorised share capital from ₹14 crore to ₹20 crore, appointment of new auditor, and re-appointment of directors.
Strong profit growth and margin improvement signal a turnaround year, while the AGM resolutions on capital expansion and new business directions could dilute equity or reshape future fundraising plans. Investors should review the full report and AGM agenda ahead of the 5th September 2025 meeting, especially the authorised capital increase which may precede a future fund raise.